TP53 and lung carcinoma: A comparison with the improved version of EarlyCDT®-Lung, a commercial autoantibody test for lung cancer early detection38, 39, reveals big overlap between our best performing autoantibodies and the autoantibodies of this test: four of the seven autoantibodies used in the EarlyCDT®-Lung test (anti-MAGEA4, anti-CTAG1 = anti-NY-ESO-1, anti-DDX53 = anti-CAGE and anti-TP53) were among the five autoantibodies with the highest sensitivities for gastric cancer; the other three autoantibodies (anti-SOX2, anti-GBU4-5 and anti-HuD) were not included in our multiplex serology measurements.